Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.
Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.
Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.
Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.
Qualigen Therapeutics has appointed Tariq Arshad, MD, MBA as the new Senior Vice President, Chief Medical Officer, aiming to enhance their oncology and viral disease pipeline. Dr. Arshad brings over 20 years of experience from top biopharmaceutical companies, including Becton Dickinson and Pfizer. His expertise in immuno-oncology is expected to significantly advance the company's therapeutic programs. This appointment comes at a crucial growth phase for Qualigen, as it develops novel treatments for cancer and viral diseases, including QN-247 and QN-165.
Qualigen Therapeutics (Nasdaq: QLGN) reported a 30% revenue increase to $1.9 million for Q1 2021, up from $1.5 million in Q1 2020. This growth was driven largely by license revenue from their FastPack® System, particularly from a deal with Yi Xin Duan Jishu in China. As of March 31, 2021, the company had approximately $21.9 million in cash. Qualigen is on track to file an IND in 2H21 for QN-165, an antiviral for COVID-19, and completed R&D for QN-247. Increased administrative expenses rose to $2.9 million due to public company overhead.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced that Michael Poirier and Amy Broidrick will present at the Benzinga Biotech Small Cap Conference on March 24, 2021. The presentation is scheduled for 11:35 am – 11:55 am EDT.
Qualigen develops therapies for cancer and infectious diseases, including promising candidates like ALAN, RAS-F, and STARS. Their FDA-approved FastPack® System is used for diagnostic tests worldwide. Interested investors may request one-on-one meetings through conference hosts.
Qualigen Therapeutics (Nasdaq: QLGN) has promoted Shishir Sinha to Chief Operating Officer, enhancing its leadership in drug development. Sinha, a 15-year veteran of the company, will leverage his expertise to oversee therapeutics project management. Qualigen focuses on developing therapeutics for cancer and infectious diseases while maintaining its FastPack System for diagnostics. Their product pipeline includes ALAN, RAS-F, and STARS. Despite advancements, challenges in clinical trials and regulatory approvals remain, posing risks to stock performance.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced that CEO Michael Poirier will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 3:00 PM EDT. This virtual event will feature numerous healthcare companies across various sectors. Qualigen focuses on innovative cancer and viral disease therapeutics, including the ALAN cancer drug candidate and the FastPack® System used for diagnostics. Their facility in Carlsbad is FDA and ISO certified, emphasizing their commitment to quality and innovation in healthcare.
Qualigen Therapeutics (NASDAQ: QLGN) has entered into a Material Evaluation and Option Agreement with University College London (UCL) to further develop its anticancer drug candidate ALAN (AS1411-GNP). This collaboration focuses on combining ALAN with G-quadruplex binders, potentially enhancing its efficacy, especially against pancreatic cancer. Qualigen plans to initiate Phase 1 human trials in 2021 for acute myeloid leukemia. The company aims to secure a worldwide commercial license for this technology, which could lead to significant advancements in cancer treatment.
Qualigen Therapeutics (Nasdaq: QLGN) announced a significant milestone in its collaboration with Yi Xin Zhen Duan Jishu of China, which initiated a payment obligation for the technology transfer of the FastPack® System. This system, known for rapid immunoassay testing, positions Qualigen for expansion in the Chinese market. The agreement includes cash payments expected in early 2021, and Qualigen may receive royalties on sales. CEO Michael Poirier expressed optimism for growth opportunities while advancing their cancer therapeutics pipeline, which is set for clinical trials this year.
Qualigen Therapeutics (Nasdaq: QLGN) will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be delivered by Michael Poirier, the Chairman and CEO of the company. Investors can access the presentation via webcast on-demand, starting January 11, 2021, on the Qualigen Therapeutics website, specifically in the Investors section.
Qualigen Therapeutics (Nasdaq: QLGN) reported significant developments in its 2021 outlook. The company has raised $12 million in a direct offering, bringing its total cash reserves to $24 million, extending its operational runway into 2022. Key initiatives for 2021 include initiating a Phase 2a clinical trial for AS1411 against COVID-19 and a Phase 1 trial for ALAN in acute myeloid leukemia. The diagnostics platform is also set for expansion, particularly with its FastPack® COVID-19 antibody test. Qualigen's management team has been strengthened with new appointments.
Qualigen Therapeutics (Nasdaq: QLGN) announced the closing of a registered direct offering, raising $12 million from a single institutional investor. The offering included the sale of 2,370,786 shares of common stock, 1,000,000 pre-funded common stock warrants, and two tranches of common stock warrants with an exercise price of $4.07 per share. A.G.P./Alliance Global Partners acted as the sole placement agent. This fundraising aims to support the development of its therapeutic pipeline focused on cancer and infectious diseases.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
